Scientific Reports · 2021 · 10 citations · 32 references
PharmacyInfectious DiseasesPharmacotherapyHepatitis PharmacotherapyMolecular VirologyVirologyAntiviral PharmacotherapyAntiviral TherapyMuscle Mass AssessmentViral HepatitisViral Hepatitis TreatmentViral PathologyDirect-acting Antiviral AgentsDirect-acting AntiviralsHepatitis C InfectionPsoas Muscle AreaSerum Zinc BiomarkersSkeletal Muscle AtrophySkeletal Muscle IndexSustained Virologic Response Duration
We aimed to evaluate factors associated with changes in skeletal muscle mass in hepatitis C virus (HCV)-infected patients after treatment with direct-acting antivirals (DAAs). Consecutive HCV-infected patients after treatment with DAA were recruited into the study. Patients who achieved sustained virological response (SVR); and had complete clinical information, preserved serum samples at baseline and SVR48, and skeletal muscle mass evaluations based on the psoas muscle mass index (PMI) on computed tomography at baseline and ≥ 12 months were included. Altogether, 70.7% of patients (41/58) showed increased PMI after DAA therapy, and mean relative PMI was significantly higher after DAA therapy than at baseline. There were no significant associations between baseline clinical factors routinely examined in clinical practice and increased PMI. Among factors reported to be associated with skeletal muscle loss in patients with chronic liver disease, serum zinc levels and total and free carnitine levels increased significantly after DAA therapy and only changes in serum free carnitine levels were significantly associated with an increased PMI (r = 0305, P = 0.020). In conclusion, increased skeletal muscle mass after successful HCV eradication by DAAs was significantly associated with increased serum-free carnitine levels. L-carnitine supplementation may be beneficial in patients with low skeletal muscle mass after DAA.
32
Sarcopenia: European consensus on definition and diagnosis
Alfonso J. Cruz‐Jentoft, Jean‐Pierre Baeyens, Jürgen M. Bauer et al. · Age and Ageing · 2010 · 11.7K citations · Full text
Hiroki Nishikawa, Makoto Shiraki, Akira Hiramatsu et al. · Hepatology Research · 2016 · 653 citations
Judith Flanagan, Peter A. Simmons, Joseph Vehige et al. · Nutrition & Metabolism · 2010 · 615 citations · Full text
Sarcopenia is a prognostic factor in living donor liver transplantation
Toshiro Masuda, Ken Shirabe, Toru Ikegami et al. · Liver Transplantation · 2013 · 288 citations